With respect to genetic alterations, the vast majority of currently druggable mutations are diagnosed in adenocarcinomas, and specifically EGFR (epidermal growth factor receptor)-activating mutations (exon 19 deletion and exon 21 L858R substitution) are among the most common ones, accounting for approximately 15% of non-squamous NSCLC cases in North American and European patients and 40%-50% of non-squamous NSCLC in Asian patients[3]. Here, EGFR is linked to adenocarcinoma.